The administration’s decision was based on the belief that Liberia has made significant progress in restoring stability and democratic governance. Liberia’s DED is set to expire at the end of March 2018, but a 12-month “wind-down” period extends the termination of DED until .
Seeking Alpha: OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the ...
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
Nasdaq: OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
Healio: VIDEO: Vevye shows minimal side effect profile for treating DED symptoms
DUBLIN--(BUSINESS WIRE)--The "Global Smart Polymers Market 2023-2028" report has been added to ResearchAndMarkets.com's offering. The Global Smart Polymers Market was valued at $23.80 Billion in 2023 ...
DUBLIN--(BUSINESS WIRE)--The "Global SVOD Forecasts Update 2029" report has been added to ResearchAndMarkets.com's offering. Global SVOD subscriptions will increase by 321 million between 2023 and ...